The Veradius device is intended to be used and operated by: adequately trained, qualified, and authorized health care professionals such as physicians, surgeons, cardiologists, and radiographers. who have full understanding of the safety information and emergency procedures as well as the capabilities and functions of the device. The device is used for radiological guidance and visualization during diagnostic, interventional, and surgical procedures on all patients except neonates (birth to 1 month), within the limits of the device is to be used in health care facilities both inside and outside the operating room. in sterile as well as nonsterile environments, in a variety of procedures.

Device Description

The proposed Veradius R1.2 is a counterbalanced C-arm with a thin flat detector x-ray system. The system consists of two main component parts: the C-arm stand (comprising X-ray generator and X-ray tube. Flat Detector and the X-ray control user interface) and the mobile viewing station (comprising the image processor, monitors, user interface for image/patient handling and optionally an integrated workstation).

AI/ML Overview

The provided text describes the Philips Veradius R1.2, an interventional fluoroscopic X-ray system, and its submission for 510(k) clearance. The focus of the submission is to demonstrate substantial equivalence to its predicate device, the Veradius R1.1 (K090590).

Here's an analysis based on the provided input:

Acceptance Criteria and Study to Prove Device Meets Acceptance Criteria

The submission focuses on establishing substantial equivalence to a predicate device, rather than defining novel acceptance criteria for new clinical performance. The acceptance criteria and supporting study are framed by demonstrating that the changes in Veradius R1.2 do not negatively impact safety and effectiveness compared to the predicate, and that the device complies with relevant standards and guidelines.

1. Table of Acceptance Criteria and Reported Device Performance

Given the nature of this 510(k) summary, the "acceptance criteria" are primarily framed around compliance with regulatory standards and demonstrating that the device maintains the safety and effectiveness of its predicate. The reported device performance is stated as meeting these criteria.

Acceptance Criteria	Reported Device Performance
Compliance with International and FDA-recognized consensus standards and FDA guidance documents. List includes: IEC 60601-2-43 (2010), IEC 60601-2-28 (2010), ISO 14971 (2007), ISO 62304 (2006), FDA Guidance "Premarket Submissions for Software Contained in Medical Devices" (May 11, 2005), FDA Guidance "510(k)'s for Solid State X-ray Imaging Devices" (August 6, 1999), FDA Guidance "Radio Frequency Wireless Technology in Medical Devices" (August 14, 2013).	The test results demonstrate that the proposed Veradius R1.2 complies with the aforementioned international and FDA-recognized consensus standards and FDA guidance.
Meets acceptance criteria and is adequate for its intended use.	The test results demonstrate that the proposed Veradius R1.2 meets the acceptance criteria and is adequate for its intended use.
Image quality is equal to the predicate.	The test results demonstrate that Image Quality is equal to the predicate.
Verification and validation tests performed to address intended use, technical claims, requirement specifications, and risk management results.	Verification and validation tests have been performed to address intended use, the technical claims, requirement specifications, image quality, and the risk management results.
Substantial equivalence to predicate device (K090590) in terms of Indications for Use, Basic Design Features, Fundamental Scientific Technology, and Operating Principle and Control Mechanism.	The proposed Veradius R1.2 is substantially equivalent to the currently marketed and predicate Veradius Mobile X-Ray system with regards to: Indications for use; Basic Design Features; Fundamental scientific technology; Operating Principle and control mechanism. The document also states, "The proposed Philips Veradius R1.2 has identical indications to the currently marketed and predicate Veradius Mobile C-arm X-ray system (Veradius R1.1)."

2. Sample size used for the test set and the data provenance

The document does not provide information on the sample size or data provenance (e.g., country of origin, retrospective/prospective) for any specific test sets related to clinical images or patient data. The non-clinical performance data section refers to "verification and validation tests" and "test results" but does not detail the datasets used.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

This information is not provided. The submission focuses on non-clinical performance data and asserts equivalence in image quality, but it does not describe any specific human expert review for establishing ground truth on image interpretation.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

No information on an adjudication method is provided. This is consistent with the lack of explicit clinical study data involving human interpretation described in the summary.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

No MRMC comparative effectiveness study was done or mentioned. The device is an X-ray system, not an AI-assisted diagnostic tool. There is no AI component described, therefore, no such comparative study involving human readers with/without AI assistance was conducted.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

No standalone algorithm-only performance study was conducted or mentioned. The device is a medical imaging system, not a standalone diagnostic algorithm.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

The document does not explicitly describe the type of ground truth used. For image quality, it states that "Image Quality is equal to the predicate," implying a comparison against established standards or perhaps internal benchmarks of the predicate device's image quality. However, the exact methodology for determining this "ground truth" for image quality, or any other performance aspect, is not detailed in terms of expert consensus, pathology, or outcomes data.

8. The sample size for the training set

No training set is mentioned or implied. The product is a hardware X-ray system with some software components consistent with its function as an imaging device. There is no indication of a machine learning or AI component that would require a "training set."

9. How the ground truth for the training set was established

As no training set is mentioned, this question is not applicable.

Summary

{0}------------------------------------------------

K133819
Page 47 of 723 Page 1 of 3

510(k) Summary

JUL 1 0 2014

This 510(k) summary is prepared in accordance with 21 CFR 807.92.

....

Date Prepared:	December 5, 2013
Manufacturer:	Philips Medical Systems Nederland B.V.Veenpluis 4-65684 PC BestThe NetherlandsEstablishment Registration Number: 3003768277
Contact Person:	Ruojuan ZhangRegulatory Affairs ManagerPhone: +31631685825Fax: +31 40 2769100E-mail: ruojuan.zhang@philips.com
Device Name:	Veradius
Classification:	Classification Name: Interventional Fluoroscopic X-Ray SystemClassification Regulation: 21 CFR892.1650Classification Panel: RadiologyDevice Class: Class IIPrimary product code: OWBSecondary product code OXO
Predicate Device	Trade Name: VeradiusManufacturer: Philips Medical Systems Nederland B.V.510(k) Clearance: K090590 (March 16, 2009)Classification Regulation: 21 CFR, Part 892.1650Classification Name: Interventional Fluoroscopic X-Ray SystemClassification Panel: RadiologyDevice Class: Class IIProduct Code: OWB; JAA

Device description:

{1}------------------------------------------------

Indications for Use:

The proposed Veradius R1.2 device is intended to be used and operated by: adequately trained, qualified, and authorized health care professionals such as physicians, surgeons, cardiologists, radiologists, and radiographers, who have full understanding of the safety information and emergency procedures as well as the capabilities and functions of the device.

The device is used for radiological guidance and visualization during diagnostic, interventional, and surgical procedures on all patients except neonates (birth to 1 month), within the limits of the device. The device is to be used in healthcare facilities both inside and outside the operating room, in sterile as well as nonsterile environments, in a variety of procedures.

Applications
Orthopedic
Neuro
Abdominal
Vascular
· Thoracic
· Cardiac

The proposed Philips Veradius R1.2 has identical indications to the currently marketed and predicate Veradius Mobile C-arm X-ray system (Veradius R1.1).

Technology:

The technology used in the development of the major components of the proposed Veradius R1.2 which includes X-ray generator, X-ray tube housing assembly, Image detection system and beam limiting device is identical to the currently marketed and predicate Veradius R1.1. The changes being proposed in this submission for the proposed Veradius R1.2, when compared to the currently marketed and predicate Veradius R1.1, are as follows:

New C-arc geometry .
Wireless LAN connection (without support of DHCP) .
New Flat Detector(model: Pixium 2630Sv) .
Additional display of dose information on Mobile Viewing Station .
DICOM Structured Dose Reporting .

Based on the information provided in this premarket notification, the Veradius R1.2 is considered substantially equivalent to the currently marketed and predicate devices in terms of:

� Indications for use;
. Basic Design Features;
Fundamental scientific technology; .
. Operating Principle and control mechanism.

Non-clinical Performance Data:

Non-clinical performance testing has been performed on the proposed Veradius R1.2 and demonstrates compliance with International and FDA-recognized consensus standards and FDA guidance document.

. IEC 60601-2-43 (2010)
IEC 60601-2-28 (2010) .
ISO 14971 (2007
ISO 62304 (2006) �
FDA Guidance document entitled, "Guidance for the Premarket ●

{2}------------------------------------------------

N133819
Page 3 of 3
Page 49 of 723

Submissions for Software Contained in Medical Devices" issued May 11, 2005.

FDA Guidance document entitled, "Guidance for the Submission of . 510(k) 's for Solid State X-ray Imaging Devices '' issued August 6, 1999
. FDA Guidance "Radio Frequency Wireless Technology in Medical Devices " issued August 14. 2013

Additionally, verification and validation tests have been performed to address intended use. the technical claims, requirement specifications, image quality and the risk management results.

The test results demonstrate that the proposed Veradius R1.2

Complies with the aforementioned international and FDA-recognized . consensus
. Meets the acceptance criteria and is adequate for its intended use.
Image Quality is equal to the predicate. .

Therefore, the proposed Veradius R1.2 is substantially equivalent to the currently marketed and predicate device (K090590, March 16, 2009) in terms of safety and effectiveness.

The subject of this premarket submission, the Veradius R1.2 did not require Clinical Performance Data: clinical studies to support substantial equivalence.

Conclusion:

The proposed Veradius R1.2 are substantially equivalent to the currently marketed and predicate Veradius Mobile X-Ray system with regards to :

� Indications for use;
. Basic Design Features;
Fundamental scientific technology: .
Operating Principle and control mechanism. .

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular arrangement of text surrounding a stylized symbol. The text reads "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular fashion. The symbol in the center resembles an abstract representation of an eagle or bird with three curved lines forming its body and wings.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration 10903 New Hamoshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

July 10. 2014

Philips Medical Systems Nederland BV % Dr. Ruojuan Zhang Regulatory Affairs Manager Veenpluis 4-6 Best 5684 PC THE NETHERLAND

Rc: K133819

Trade/Device Name: Veradius Regulation Number: 21 CFR 892.1650 Regulation Name: Image-intensified fluoroscopic x-ray system Regulatory Class: II Product Code: JAA, OWB Dated: April 3, 2014 Received: April 7, 2014

Dear Dr. Zhang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (sec above) into cither class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA *s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820): and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act): 21 CFR 1000-1050.

{4}------------------------------------------------

Page 2-Dr. Zhang

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Smh.7)

for

Janine M. Morris Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

Indications for Use

510(k) Number (if known) K133819

Device Name Veradius

Indications for Use (Describe)

Applications

· Orthopedic
· Neuro
· Abdominal
: Vascular
· Thoracic
· Cardiac

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

•DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Regulation Number and Section

§ 892.1650 Image-intensified fluoroscopic x-ray system.

(a)
Identification. An image-intensified fluoroscopic x-ray system is a device intended to visualize anatomical structures by converting a pattern of x-radiation into a visible image through electronic amplification. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II (special controls). An anthrogram tray or radiology dental tray intended for use with an image-intensified fluoroscopic x-ray system only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9. In addition, when intended as an accessory to the device described in paragraph (a) of this section, the fluoroscopic compression device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.